FINWIRES · TerminalLIVE
FINWIRES

Syntara Receives Positive US FDA Feedback for Clinical Trial of Bone Marrow Cancer Treatment

By

Syntara (ASX:SNT) received positive feedback from the US Food and Drug Administration following a type C meeting, supporting the design of its planned phase 2b clinical trial of amsulostat for the treatment of myelofibrosis, according to a Tuesday filing with the Australian bourse.

The primary endpoint of the phase 2b study will be the achievement of a 50% reduction in the total symptom score following nine months of treatment, with about 100 patients expected to be enrolled, per the filing.

The positive feedback from the US FDA allows for amsulostat's progression into late-stage clinical development and paves the way for further engagement with prospective commercial partners, the company said.

Myelofibrosis is a type of bone marrow cancer where the accumulation of scar tissue leads to a loss of red and white blood cells and platelets.

Related Articles

Asia

Shenzhen Dobot Completes A Share Listing Filing in China

Shenzhen Dobot (HKG:2432) completed the A share listing filing to go public in China, the firm said in a statement to the Hong Kong bourse Monday.The robotics services company's shares fell nearly 1% in late morning trade Tuesday.The firm submitted application materials in regards to the proposed A share offering on the ChiNext Market of the Shenzhen Stock Exchange.The filing was accepted by the exchange, the firm said.

HKG:2432
Asia

Daido to Raise HK$11 Million via Share Subscription; Shares Rise 14%

Daido Group (HKG:0544) aims to raise net proceeds of about HK$11.4 million through a subscription of new shares under its general mandate, according to a Monday Hong Kong bourse filing.Shares of the warehouse, logistics, and trading company rose nearly 14% in morning trade Tuesday.The company agreed to issue about 5.8 million subscription shares at HK$2.00 each.The subscription price represents a premium of about 13.6% to the stock's last close and about 14.3% to the five-day average closing price, the filing showed.Proceeds will be used mainly for debt repayment and general working capital.

HKG:0544
Asia

Nine Entertainment Shares Slide After Australian Government Opens Consultation on News Bargaining Incentive

Nine Entertainment (ASX:NEC) shares fell nearly 1% in recent Tuesday trade after the Australian government opened a consultation on draft legislation to establish a News Bargaining Incentive, a policy framework designed to force major digital platforms like Meta, Google, and TikTok to pay for Australian news content.Nine Entertainment is the publisher of The Australian Financial Review and has a current commercial agreement with Google, according to an AFR report.In a Tuesday statement announcing the consultation, the government said it encourages digital platforms to enter commercial deals with news publishers "as the preferred model." However, platforms who decide not to do so will be required to pay a charge as a proportion of their revenue, with the collected levies distributed back into the news media sector.The initiative, which comes after Meta said it would not renew its commercial deals, proposes a 2.25% tax on the revenue of tech companies that do not negotiate agreements, AFR reported.Submissions on the government's consultation close on May 18.

ASX:NEC